Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
0.2680
+0.0007 (+0.26%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business
October 20, 2023
Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc.
Via
Benzinga
Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement
October 18, 2023
Short-acting psychedelics biotech Small Pharma Inc.
Via
Benzinga
Small Pharma Obtains Final Order Approving Arrangement
October 17, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
October 16, 2023
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution
Via
Benzinga
Exposures
Product Safety
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates
October 13, 2023
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc.
Via
Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting
October 13, 2023
Via
Investor Brand Network
Cybin Announces Results of Annual and Special Meeting of Shareholders
October 12, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
October 06, 2023
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
Via
Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit
October 06, 2023
Via
Investor Brand Network
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
October 06, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 04, 2023
Via
Investor Brand Network
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
October 04, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment
October 03, 2023
Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company developing novel psychedelic-based mental health treatments, has completed dosing of the final participant cohort in the
Via
Benzinga
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
October 03, 2023
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management...
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Wraps Up Phase 2 Study Dosing for Final Cohort
October 03, 2023
Via
Investor Brand Network
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
October 03, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
October 02, 2023
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Positive Top-Line Data Gathered from Small Pharma Study
September 27, 2023
Via
Investor Brand Network
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
September 27, 2023
From
Cybin Inc.
Via
Business Wire
Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression
September 26, 2023
Clinical-stage psychedelics biotech Cybin Inc.
Via
Benzinga
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results
September 26, 2023
New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.
Via
Benzinga
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
September 26, 2023
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
September 26, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Cantor Global Healthcare Conference
September 25, 2023
Via
Investor Brand Network
Cybin to Participate in the Cantor Global Healthcare Conference
September 25, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting
September 22, 2023
Via
Investor Brand Network
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
September 21, 2023
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive...
Via
Benzinga
Cybin Announces Date of Annual and Special Meeting of Shareholders
September 21, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Enrollment in Phase 2 CYB003 Study
September 21, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
September 21, 2023
From
Cybin Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.